We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.34B
1-Year Est. Return
204.53%
This Fund
S&P 500
This Quarter
Est. Return
+16.5%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.25B
AUM Growth
+$451M
(+25%)
Cap. Flow
+$438M
Cap. Flow
% of AUM
19.47%
Top 10 Holdings %
Top 10 Hldgs %
64.9%
Holding
86
New
20
Increased
10
Reduced
4
Closed
12
Top Buys
| 1 |
Nuvation Bio
NUVB
|
+$148M |
| 2 |
AnaptysBio
ANAB
|
+$99.1M |
| 3 |
Kura Oncology
KURA
|
+$60.7M |
| 4 |
Edgewise Therapeutics
EWTX
|
+$39.7M |
| 5 |
Design Therapeutics
DSGN
|
+$38.4M |
Top Sells
| 1 |
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
|
+$44.3M |
| 2 |
Geron
GERN
|
+$30.1M |
| 3 |
VINC
Vincerx Pharma, Inc. Common Stock
VINC
|
+$10M |
| 4 |
Aclaris Therapeutics
ACRS
|
+$9.77M |
| 5 |
CMAX
CareMax, Inc. Class A Common Stock
CMAX
|
+$7.51M |
Sector Composition
| 1 | Healthcare | 98.52% |
| 2 | Financials | 0.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$446M
| $277M | 12.33% |
11,034,280
+1,607,640
| +17% | +$30.2M |
|
2
Xencor
XNCR
$1.11B
| $211M | 9.38% |
4,900,306
+353,234
| +8% | +$16.7M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $190M | 8.44% |
2,999,315
+159,431
| +6% | +$7.32M |
|
|
4
AnaptysBio
ANAB
$1.68B
| $154M | 6.85% |
7,151,624
+3,928,300
| +122% | +$99.1M |
|
|
5
Nuvation Bio
NUVB
$2.03B
| $138M | 6.16% |
+13,247,017
| New | +$148M |
|
6
Relay Therapeutics
RLAY
$4.15B
| $119M | 5.27% |
3,429,363
+228,714
| +7% | +$9.93M |
|
7
ARS Pharmaceuticals
SPRY
$721M
| $111M | 4.92% |
2,533,635
| – | – |
|
|
8
Kura Oncology
KURA
$999M
| $104M | 4.64% |
3,692,637
+1,919,600
| +108% | +$60.7M |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $79.5M | 3.54% |
464,298
| – | – |
|
10
Oric Pharmaceuticals
ORIC
$1.11B
| $75.8M | 3.37% |
3,092,218
| – | – |
|
11
Shattuck Labs
STTK
$606M
| $71.9M | 3.2% |
2,458,259
+1,405
| +0.1% | +$59K |
|
12
Nurix Therapeutics
NRIX
$2.43B
| $62.8M | 2.79% |
2,019,019
+475,000
| +31% | +$18M |
|
13
Arcus Biosciences
RCUS
$3.52B
| $61.7M | 2.74% |
2,195,892
| – | – |
|
14
Solid Biosciences
SLDB
$926M
| $50.9M | 2.26% |
613,513
+81,666
| +15% | +$9.04M |
|
|
RNAM
15
DELISTED
Avidity Biosciences
RNAM
| $45.9M | 2.04% |
2,103,950
| – | – |
|
|
16
Edgewise Therapeutics
EWTX
$4.28B
| $39.8M | 1.77% |
+1,224,175
| New | +$39.7M |
|
17
Neurogene
NGNE
$783M
| $38.4M | 1.71% |
156,135
| – | – |
|
|
BCEL
18
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
| $37.2M | 1.65% |
2,426,685
| – | – |
|
|
19
Design Therapeutics
DSGN
$847M
| $34M | 1.51% |
+1,137,940
| New | +$38.4M |
|
|
GRTS
20
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $32.3M | 1.43% |
3,421,287
| – | – |
|
21
AC Immune
ACIU
$243M
| $27.8M | 1.23% |
3,648,163
+1,237,923
| +51% | +$8.84M |
|
|
AKUS
22
DELISTED
Akouos Inc
AKUS
| $27.4M | 1.22% |
1,975,984
| – | – |
|
23
Ovid Therapeutics
OVID
$463M
| $24.4M | 1.09% |
+6,082,200
| New | +$20.2M |
|
24
Arvinas
ARVN
$533M
| $21.1M | 0.94% |
+318,704
| New | +$24.4M |
|
|
KDNY
25
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $19.4M | 0.86% |
1,250,001
| – | – |
|
Similar funds
G
MC
BAM
CC
HFM
NO
ST
MFAM